Skip to main content
Erschienen in: BMC Cancer 1/2005

Open Access 01.12.2005 | Research article

Breast conserving surgery versus mastectomy: cancer practice by general surgeons in Iran

verfasst von: Massoome Najafi, Mandana Ebrahimi, Ahmad Kaviani, Esmat Hashemi, Ali Montazeri

Erschienen in: BMC Cancer | Ausgabe 1/2005

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN

Abstract

Background

There appear to be geographical differences in decisions to perform mastectomy or breast conserving surgery for early-stage breast cancer. This study was carried out to evaluate general surgeons' preferences in breast cancer surgery and to assess the factors predicting cancer practice in Iran.

Methods

A structured questionnaire was mailed to 235 general surgeons chosen from the address list of the Iranian Medical Council. The questionnaire elicited information about the general surgeons' characteristics and about their work experience, posts they have held, number of breast cancer operations performed per year, preferences for mastectomy or breast conserving surgery, and the reasons for these preferences.

Results

In all, 83 surgeons returned the completed questionnaire. The results indicated that only 19% of the surgeons routinely performed breast conserving surgery (BCS) and this was significantly associated with their breast cancer case load (P < 0.01). There were no associations between BCS practice and the other variables studied. The most frequent reasons for not performing BCS were uncertainty about conservative therapy results (46%), uncertainty about the quality of available radiotherapy services (32%), and the probability of patients' non-compliance in radiotherapy (32%).

Conclusion

The findings indicate that Iranian surgeons do not routinely perform BCS as the first and the best treatment modality. Further research is recommended to evaluate patients' outcomes after BCS treatment in Iran, with regard to available radiotherapy facilities and cultural factors (patients' compliance).
Hinweise

Competing interests

The author(s) declare that they have no competing interests.

Authors' contributions

MN contributed to the study design, data collection and analysis, and wrote the first draft. ME contributed to the study design and data analysis. AK contributed to the study design and data collection. EH contributed to the data collection. AM contributed to the data analysis and wrote the final draft.

Background

Many randomized clinical trials have demonstrated that patient survival rates are similar after treatment by mastectomy or by conservative surgery and radiotherapy [14]. However, the National Institute of Health Consensus Conference concluded that for most women with early-stage breast cancers (stages I and II), breast conservation surgery (BCS) is an appropriate method of treatment [5]. Despite these findings, mastectomy remains the most prevalent surgical treatment for early-stage breast cancer in many parts of the world. In Iran, BCS is an uncommon modality for this condition. For example, in one study in Isfahan University of Medical Sciences, 386 breast cancer patients were reviewed and mastectomy was found to be the most prevalent surgical treatment [6]. Similarly, in another study in Tehran University of Medical Sciences, 348 breast cancer patients of whom 50% had stage I or stage II breast cancer were evaluated, and it was found that only 22 patients underwent BCS [7].
It is argued that one factor influencing choice of treatment in breast cancer patients is the attitude of the operating surgeon. There is evidence that most women follow surgeons' recommendations, their primary source of information about treatment options. Studies have shown that surgeons recommended a specific treatment option in 69% of cases; in 89% of these cases they offered mastectomy and in 11% BCS. The rates of compliance with these recommendations were reported to be 93% and 89% respectively [8].
The present study was designed to evaluate the preferences of surgeons in Iran regarding breast cancer treatment and the factors influencing the type of treatment recommended.

Methods

A descriptive study was conducted to investigate cancer practice among general surgeons in Iran. A specially designed questionnaire was mailed to a sample of 235 general surgeons, selected randomly from the Iranian Medical Council's address list for general surgeons and including a few surgical oncologists. All general surgeons (n = 1977, 1831 male and 146 female) belong to the Council. It is worth noting that in Iran, gynecologists and plastic surgeons do not perform breast cancer surgery. The sample size was determined by expectations of the rate of BCS treatment by the general surgeons: it was estimated that at best 15% and at worst 5% of the surgeons might perform BCS. Based on this assumption, a sample of 81 surgeons would give results with a 99% confidence level. To achieve this sample size it was decided to mail the questionnaire to 235 general surgeons, nearly three times more than needed. The questionnaire addressed the surgeons' characteristics including age, gender, work experience, posts held (teaching hospitals or private and public institutions), and number of breast cancer patients treated per year. In addition, respondents were asked whether they routinely performed BCS, and if the answer was "no" the reasons were solicited. Data were analyzed in a descriptive fashion, reporting numbers and percentages and using the chi-square test (Fisher's exact test) where necessary.

Results

In all, 83 completed questionnaires were returned, giving a response rate of 33%. The characteristics of the study sample are shown in Table 1. The mean age of the respondents was 55.2 years (SD = 12.3; range 32 to 80). Most surgeons were male (n = 75, 90%), had more than 10 years work experience (76%), and were working at public or private centers (75%). For 80% of the surgeons surveyed, the average number of breast cancer patients treated per year was less than 20; 20% reported that their annual case-load was more than 20.
Table 1
The characteristics of the study sample
 
Number
%
Age (years)
  
<40
14
17
40–59
37
45
≥60
32
38
Mean (SD)
55.2 (12.3)
 
Gender
  
Female
8
10
Male
75
90
City of practice
  
Tehran (the capital)
20
24
Other cities
63
76
Work experience (years)
  
≤10
20
24
>10
63
76
Mean (SD)
23.2 (12.7)
 
Occupation status
  
Working at a teaching hospital.
21
25
Working at a public/private hospital
62
75
Breast cancer case load (patient/per year, n = 70)
  
≤20
56
80
>20
14
20
Preferred type of surgery for breast cancer
  
Mastectomy
67
81
Breast conserving surgery
16
19
Only 19% of the surgeons said that they performed BCS routinely. Table 2 shows the reasons given for avoiding BCS. The most frequent reason was the surgeons' uncertainty about the results of breast conserving surgery (46.3%). The other most frequently-stated barriers to performing BCS were uncertainty about radiotherapy services and patients' non-compliance in radiotherapy (32.8%). Of the factors studied, only breast cancer case-load had a statistically significant association with performance of BCS (P = 0.007). The results are shown in Table 3.
Table 2
Reasons stated by the surgeons for avoiding conservative therapy*
 
Number
% of the study sample
Uncertainty about results of conservative therapy
32
46.3
Uncertainty about radiotherapy services
22
32.8
Probability of patient incompliance
22
32.8
Unavailability of radiotherapy services
17
25.4
Higher cost of conservative therapy
12
17.9
Lack of enough experience for performing BCS
10
14.9
* The total exceeds the sample size since each respondent could state several reasons.
Table 3
Association between breast cancer practice and the respondents' characteristics
 
Breast conservation No. (%)
Mastectomy No. (%)
P value
Gender
  
0.35
Male
14 (82)
61 (92)
 
Female
3 (18)
5 (8)
 
Age (years)
  
0.60
<40
4 (24)
10 (15)
 
40–59
6 (35)
31 (47)
 
≥60
7 (41)
25 (38)
 
Work experience
  
1.0
≤10
4 (24)
16 (24)
 
>10
13 (76)
50 (76)
 
Working at a teaching hospital
  
0.12
Yes
7 (41)
14 (21)
 
No
10 (59)
52 (79)
 
Breast cancer case load of the surgeon (n = 70)
  
0.007
≤20
8 (53)
48 (87)
 
>20
7 (47)
7 (13)
 

Discussion

Breast-conserving surgery is a treatment modality for early-stage breast cancer that causes less physical disfigurement and psychological trauma to the patient. Many prospective randomized trials have demonstrated that overall and disease-free survival rates for early-stage breast cancer are equivalent after mastectomy or BCS with postoperative radiotherapy [24], [8, 9]. There appear to be geographical differences in the surgical treatment of early-stage breast cancer. Evidence suggests that physician recommendation exerts the most significant influence on surgical treatment selection for the majority of women [10].
In this study only 19% of surgeons used BCS in their practice while the remaining 81% performed mastectomy. This concurs with two other studies, performed in Tehran and Isfahan University of Medical Sciences, showing that mastectomy was the most prevalent surgical treatment for breast cancer patients [6, 7]. However, it is arguable that BCS rates would rise in Iran if general surgeons, for example, could benefit from continuing medical education, attend scientific meetings, and have access to modern textbooks and current journals. Discussion of these topics lies beyond the scope of this study. Briefly, it should be noted that there is a National Society of Surgeons in Iran. In addition to other scientific meetings that address oncology issues, members of this society have their own annual and occasional scientific meetings, and usually receive printed educational materials including issues on current technology. At present all surgeons and radiation therapists in teaching hospitals and many working in the private sector are Board-certified. Some modern radiation therapy facilities in Iran are very similar to existing facilities in developed countries. Furthermore, we suspect that predicting patient non-compliance with radiation therapy might be subjective impressions on the part of the surgeons, since there is no evidence or published data to indicate that patient compliance with radiation therapy is low.
The findings indicated that gender had no effect on the performance of BCS. This may be due to the small number of female surgeons in this study. Similarly, in a study comparing rates of BCS between male and female surgeons, no statistically significant difference was found between the two groups [11]. However, it is interesting that in our study, 14 out of the 75 male surgeons (19%) indicated that they routinely perform BCS, while 3 out of the 8 female surgeons (38%) stated that they performed BCS.
We found that the surgeons' age and work experience was not significantly associated with performing BCS; other studies have shown that younger surgeons are more likely to perform BCS. In one retrospective study that reviewed the medical records of 952 patients, it was found that surgeons who graduated after 1960 performed BCS more frequently than those who graduated before 1960 [12]. Another study showed that surgeons who graduated after 1980 performed BCS at a significantly higher rate than those who graduated before 1961 [13]. However, the mean age of our study sample was 55.2 (SD = 12.3) years and the mean duration of work experience was 23.2 years (SD = 12.7). In other words, most of our participants were old; only 17% were relatively young. This might explain why most surgeons in this study stated that they performed mastectomy. This is also consistent with the fact that mastectomy is the most prevalent surgical therapy for breast cancer in our teaching hospitals [6, 7]. However, the findings from the present study indicate that there is a trend towards more BCS at teaching hospitals, and it is very likely that a bigger sample would show a significant difference between teaching hospitals and private institutes.
There was a statistically significant association between the experience of the surgeons (measured by the number of beast cancer patients treated per year) and performance of BCS. Surgeons treating more than 20 breast cancer patients per year had a statistically significant higher BCS rate (P = 0.007). Few studies have reported a correlation between the surgeons' experience and their breast conservation surgery rates. A population-based study found that patients treated by surgeons with higher breast cancer case-loads were more likely to receive breast conservation therapy [14]. A survey of surgeons carried out in 1986 showed no evidence of a relationship between the number of breast surgery operations performed and the rate of conservative surgery; but in a repeat survey in 1990, when the overall conservative surgery rate had risen to 42%, a significant association was found for surgeons treating 20 or more patients per year [13].
In this study, the most common reasons given for avoiding BCS were uncertainty about the results of breast conservation therapy (46.3%), uncertainty about the quality of available radiotherapy services (32%), and probability of patient non-compliance (32%). Other reasons noted by the surgeons were the higher cost of breast conserving therapy (17.9%), non-availability of radiotherapy facilities (25.4%), and insufficiency of experience with the BCS technique (14.9%). A few studies have reported surgeons' reasons for avoiding BCS. In one study, the majority of surgeons believed that long-term disease-free survival was equal for mastectomy and BCS, and the preference for mastectomy was mostly due to the inconvenience of radiotherapy [15].

Conclusion

In conclusion, considering the study limitations (e.g. the sample size was small, the surgeons were predominantly old and only eight of them were female), the findings suggest that the overall performance of BCS in Iran is low. In order to increase the rate of conservation therapy there is need to study the outcomes of breast conservation therapy in Iran to determine overall and disease-free survival and local recurrence rates. At the same time the quality of available radiotherapy services should be evaluated. Perhaps this information might help to improve breast cancer outcomes.

Competing interests

The author(s) declare that they have no competing interests.

Authors' contributions

MN contributed to the study design, data collection and analysis, and wrote the first draft. ME contributed to the study design and data analysis. AK contributed to the study design and data collection. EH contributed to the data collection. AM contributed to the data analysis and wrote the final draft.
Literatur
1.
Zurück zum Zitat Veronesi U, Salvadori B, Luini A, Greco M, Saccozzi R, del Vecchio M, Mariani L, Zurrida S, Rilke F: Breast conservation is a safe method in patients with small cancer of the breast. Long term results of three randomized trials on 1,973 patients. Eur J Cancer. 1995, 31A: 1574-1579. 10.1016/0959-8049(95)00271-J.CrossRefPubMed Veronesi U, Salvadori B, Luini A, Greco M, Saccozzi R, del Vecchio M, Mariani L, Zurrida S, Rilke F: Breast conservation is a safe method in patients with small cancer of the breast. Long term results of three randomized trials on 1,973 patients. Eur J Cancer. 1995, 31A: 1574-1579. 10.1016/0959-8049(95)00271-J.CrossRefPubMed
2.
Zurück zum Zitat Arriagada R, Le MG, Rochard F, Contesso G: Conservative treatment versus mastectomy in early breast cancer: patterns of failure with 15 years of follow-up data. Institute Gustave-Roussy Breast Cancer Group. J Clin Oncol. 1996, 14: 1558-1564.PubMed Arriagada R, Le MG, Rochard F, Contesso G: Conservative treatment versus mastectomy in early breast cancer: patterns of failure with 15 years of follow-up data. Institute Gustave-Roussy Breast Cancer Group. J Clin Oncol. 1996, 14: 1558-1564.PubMed
3.
Zurück zum Zitat Fisher B, Anderson S, Redmond CK, Wolmark N, Wickerham DL, Cronin WM: Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med. 1995, 333: 1456-1461. 10.1056/NEJM199511303332203.CrossRefPubMed Fisher B, Anderson S, Redmond CK, Wolmark N, Wickerham DL, Cronin WM: Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med. 1995, 333: 1456-1461. 10.1056/NEJM199511303332203.CrossRefPubMed
4.
Zurück zum Zitat Jacobson JA, Danforth DN, Cowan KH, d'Angelo T, Steinberg SM, Pierce L, Lippman ME, Lichter AS, Glatstein E, Okunieff P: Ten-year results of a comparison of conservation with mastectomy in the treatment of stage I and II breast cancer. N Engl J Med. 1995, 332: 907-911. 10.1056/NEJM199504063321402.CrossRefPubMed Jacobson JA, Danforth DN, Cowan KH, d'Angelo T, Steinberg SM, Pierce L, Lippman ME, Lichter AS, Glatstein E, Okunieff P: Ten-year results of a comparison of conservation with mastectomy in the treatment of stage I and II breast cancer. N Engl J Med. 1995, 332: 907-911. 10.1056/NEJM199504063321402.CrossRefPubMed
5.
Zurück zum Zitat NIH Consensus Conference. Treatment of early-stage breast cancer. JAMA. 1991, 265: 391-395. 10.1001/jama.265.3.391. NIH Consensus Conference. Treatment of early-stage breast cancer. JAMA. 1991, 265: 391-395. 10.1001/jama.265.3.391.
6.
Zurück zum Zitat Mousavi R, Akbari ME: Epidemiologic study of breast diseases in Isfahan. PhD thesis. 1993, Isfahan University of Medical Sciences, Department of Surgery Mousavi R, Akbari ME: Epidemiologic study of breast diseases in Isfahan. PhD thesis. 1993, Isfahan University of Medical Sciences, Department of Surgery
7.
Zurück zum Zitat Atai Fashtami H, Atri M: A retrospective study of 350 cases of breast cancer: histological type, sex, stage, treatment and the results of 10 year follow-up. PhD thesis. 1994, Tehran University of Medical Sciences, Department of Surgery Atai Fashtami H, Atri M: A retrospective study of 350 cases of breast cancer: histological type, sex, stage, treatment and the results of 10 year follow-up. PhD thesis. 1994, Tehran University of Medical Sciences, Department of Surgery
8.
Zurück zum Zitat Kotwall CA, Maxwell JG, Covington DL, Churchill P, Smith SE, Covan EK: Clinicopathologic factors and patient perceptions associated with surgical breast-conserving treatment. Ann Surg Oncol. 1996, 3: 169-175.CrossRefPubMed Kotwall CA, Maxwell JG, Covington DL, Churchill P, Smith SE, Covan EK: Clinicopathologic factors and patient perceptions associated with surgical breast-conserving treatment. Ann Surg Oncol. 1996, 3: 169-175.CrossRefPubMed
9.
Zurück zum Zitat Van Donegan JA, Bartelink H, Fentiman IS, Lerut T, Mignolet F, Olthuis G, van der Schueren E, Sylvester R, Winter J, van Zijl K: Randomized clinical trial to assess the value of breast-conserving therapy in stage I and II breast cancer: EORTC 10801 trial. J Natl Cancer Inst Monogr. 1992, 11: 15-18. Van Donegan JA, Bartelink H, Fentiman IS, Lerut T, Mignolet F, Olthuis G, van der Schueren E, Sylvester R, Winter J, van Zijl K: Randomized clinical trial to assess the value of breast-conserving therapy in stage I and II breast cancer: EORTC 10801 trial. J Natl Cancer Inst Monogr. 1992, 11: 15-18.
10.
Zurück zum Zitat Harris JR, Lippman ME, Morrow M, Osborne CK: Disease of the breast. 2000, Lippincot Williams & Wilkins, 2 Harris JR, Lippman ME, Morrow M, Osborne CK: Disease of the breast. 2000, Lippincot Williams & Wilkins, 2
11.
Zurück zum Zitat Weinberg E, Woods S, Grannan K, Hendy MP: The influence of the gender of the surgeon on surgical procedure preference for breast cancer. Am Surg. 2002, 68: 398-400.PubMed Weinberg E, Woods S, Grannan K, Hendy MP: The influence of the gender of the surgeon on surgical procedure preference for breast cancer. Am Surg. 2002, 68: 398-400.PubMed
12.
Zurück zum Zitat Kotwall C, Covington D, Churchill P, Brinker C, Weintritt D, Maxwell JG: Breast conservation surgery for breast cancer at a regional medical center. Am J Surg. 1998, 176: 510-514. 10.1016/S0002-9610(98)00254-2.CrossRefPubMed Kotwall C, Covington D, Churchill P, Brinker C, Weintritt D, Maxwell JG: Breast conservation surgery for breast cancer at a regional medical center. Am J Surg. 1998, 176: 510-514. 10.1016/S0002-9610(98)00254-2.CrossRefPubMed
13.
Zurück zum Zitat Kotwall CA, Covington DL, Rutledge R, Churchill MP, Meyer AA: Patient, hospital and surgeon factors associated with breast conservation surgery. A statewide analysis in North Carolina. Ann Surg. 1996, 224: 419-426. 10.1097/00000658-199610000-00001.CrossRefPubMedPubMedCentral Kotwall CA, Covington DL, Rutledge R, Churchill MP, Meyer AA: Patient, hospital and surgeon factors associated with breast conservation surgery. A statewide analysis in North Carolina. Ann Surg. 1996, 224: 419-426. 10.1097/00000658-199610000-00001.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Taylor R, Stubbs JM, Langlands AO, Boyages J: Predictors of mastectomy for women with breast cancer in greater western region of Sydney. Breast J. 1999, 5: 116-121. 10.1046/j.1524-4741.1999.00135.x.CrossRefPubMed Taylor R, Stubbs JM, Langlands AO, Boyages J: Predictors of mastectomy for women with breast cancer in greater western region of Sydney. Breast J. 1999, 5: 116-121. 10.1046/j.1524-4741.1999.00135.x.CrossRefPubMed
15.
Zurück zum Zitat Stafford D, Szczys R, Becker R, Anderson J, Bushfield S: How breast cancer treatment decisions are made by women in North Dakota. Am J Surg. 1997, 176: 515-519. 10.1016/S0002-9610(98)00257-8.CrossRef Stafford D, Szczys R, Becker R, Anderson J, Bushfield S: How breast cancer treatment decisions are made by women in North Dakota. Am J Surg. 1997, 176: 515-519. 10.1016/S0002-9610(98)00257-8.CrossRef
Metadaten
Titel
Breast conserving surgery versus mastectomy: cancer practice by general surgeons in Iran
verfasst von
Massoome Najafi
Mandana Ebrahimi
Ahmad Kaviani
Esmat Hashemi
Ali Montazeri
Publikationsdatum
01.12.2005
Verlag
BioMed Central
Erschienen in
BMC Cancer / Ausgabe 1/2005
Elektronische ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-5-35

Weitere Artikel der Ausgabe 1/2005

BMC Cancer 1/2005 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.